Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: DCC functions as a tumor suppressor and is altered in various tumors, including neuroendocrine neoplasms. Netrin (NTN)-1 serves as the primary ligand for DCC. Operating as a dependence receptor, DCC induces apoptosis without NTN and promotes cell survival in its presence. In some cancers like small cell lung cancer and neuroblastoma, upregulation of NTN-3 rather than NTN-1 has been observed. However, the precise involvement of NTNs and DCC in PNEN remains unclear.
Conference:
Presenting Author: Sela Peremen L
Authors: Sela Peremen L, Telerman A, Peshes Yaloz N, Tirosh A,
Keywords: neuroendocrine, netrin, pancreatic neuroendocrine tumor, dcc,
Introduction: Future improvements in NETs therapy depend on treatments tailored to tumor cell characteristics, microenvironment and inflammatory status. We recently reported selective downregulation of microRNAs (miRs) -29 and -223 in serum of NET patients, suggesting a possible role in NET disease.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author:
Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Avniel-Polak S
Authors: Avniel-Polak S, Leibowitz G, Gross D, Grozinsky-Glasberg S,
#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes
Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect. The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Gentilin E
Authors: Gentilin E, Gagliano T, Benfini K, Di Pasquale C, Falletta S,
Keywords: mitotane, adrenocortical cancer, pituitary,
Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Reimann C
Authors: Reimann C, Kaemmerer D, Specht E, Wirtz R, Lupp A,
Keywords: neuroendocrine, tumor, SCLC, CXCR4, IHC,